Laboratory diagnosis of hereditary thrombophilia

Seminars in Thrombosis and Hemostasis

Volumn 24, Issue 4, 1998, Pages 309-320

  Michiels, Jan Jacques ^a,b   Hamulyák, Karly ^c  

^a Goodheart Institute   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antithrombin; APC resistance; Protein C; Protein S; Thromboembolism; Thrombophilia; Thrombosis

Indexed keywords

ANTITHROMBIN; PROTEIN C; PROTEIN S; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ANTIGEN SPECIFICITY; BINDING SITE; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GENETIC DISORDER; HETEROZYGOTE; HUMAN; LABORATORY DIAGNOSIS; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS;

EID: 0031684714     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996019     Document Type: Review

References (65)

1. Rosenberg RD. Regulation of the hemostatic mechanism. In: G Stamatoyannapoulos, AW Nienhuis, PW Majerus, H Varmus, eds. The Molecular Basis of Blood Diseases. Philadelphia: Saunders; 1987:534-574
2. Stenflo J, Dahlbäck B. Vitamin K-dependent proteins. In: G Stamatoyannapoulos, AW Nienhuis, PW Majerus, H Varmus, eds. The Molecular Basis of Blood Diseases. Philadelphia: Saunders; 1994:565-598
3. Pittet J-L, de Moerloose Ph, Reber G, et al. VIDAS D-Dimer: fast quantitative ELISA for measuring D-Dimer in plasma. Clin Chem 1996;42:410-415
4. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemostas 1995;74:1-6
5. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemostas 1997;78:386-391
6. Bajzar L, Manuel R, Nesheim M. Purification and characterization of TAFI, a thrombin activatable fibrinolysis inhibitor. J Biol Chem 1996;271:14477-14484
7. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulant and fibrinolytic cascades through the thrombin/thrombomodulin complex. J Biol Chem 1996;271:16603-16608
8. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965;13:516-530
9. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981;68:1370-1373
10. Bertina RM, Broekmans AW, Van der Linden IK, Mertens K. Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemostas 1982;48:1-5
11. Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med 1983;309:340-344
12. Comp PC, Nixon RR, Cooper MR, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984;74:2082-2088
13. Broekmans AW, Bertina RM, Reinalda Poot J. Hereditary protein S deficiency and venous thromboembolism. A study in three Dutch families. Thromb Haemostas 1985;53:273-277
14. Malm J, Laurell M, Nilsson IM, Dahbäck B. Thromboembolic disease, critical evaluation of laboratory investigation. Thromb Haemostas 1992;68:7-13
15. Heijboer H, Brandjes D, Büller HR, Sturk A, ten Cate JW. Deficiencies of coagulation inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323:1512-1516
16. Taberno MD, Tomas JF, Alberca I, Orfao I, Borrasca AL, Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 1991;36: 249-254
17. Miletich J, Sherman I, Broze G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987;317:991-996
18. Dahbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-1008
19. Bertina RM, Koeleman PC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67
20. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342:1503-1506
21. Svensson PJ, Dahlbäck B. Resistance to activated protein C as basis for venous thrombosis. N Engl J Med 1994;330:517-522
22. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-2703
23. Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CRM. The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population. Br J Haematol 1997; 98:353-355
24. Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′untranslated region of the prothrombin gene. Br J Haematol 1997;98:907-909
25. Öhlin A-K, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45-year old male presenting with thromboembolic disease. Blood 1995;85:330-336
26. Öhlin A-K, Norlund L, Marlar RA. Thrombomodulin gene variations and thromboembolic disease. Thromb Haemostas 1997; 78:396-400
27. Rosén SB, Sturk A. Activated protein C resistance, a major risk factor for thrombosis. Eur J Chem Clin Biochem 1997;35: 501-516
28. Lane DA, Olds RJ, Boisclair M, et al. Antithrombin III mutation database: First update. Thromb Haemostas 199;70:361-369
29. Perry D. Antithrombin and its inherited deficiencies. Blood Rev 1994;8:37-55
30. Lane DA, Bayston T, Lods RJ, et al. Antithrombin mutation database: 2nd (1997) update. Thromb Haemostas 1997;77:197-211
31. Broze GJ, Tolefsen DM. Regulation of blood coagulation by protease inhibitors. In: G Stamatoyannapoulos, AW Nienhuis, PW Majerus, H Varmus, eds. The Molecular Basis of Blood Diseases. Philadelphia: Saunders; 1994:629-656
32. Hirsh J, Heparin. N Engl J Med 1991;324:1565-1574
33. Hirsh J, Levin MN. Low molecular weight heparin. Blood 1992; 79:1-17
34. Hirsh J. Low molecular weight heparin. Thromb Haemostas 1993;70:204-207
35. Dahlbäck B, Stenflo J. The protein C anticoagulant system. In: G Stamatoyannapoulos, AW Nienhuis, PW Majerus, H Varmus, eds. The Molecular Basis of Blood Diseases. Philadelphia: Saunders: 1994:599-628
36. Dahbäck B. The protein C anticoagulant system: Inherited defects as basis for venous thrombosis. Thromb Res 1995;77: 1-43
37. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part I. Thromb Haemostas 1996;76:651-662
38. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part II. Thromb Haemostas 1996;76:824-834
39. Bertina. An International collaborative study on the performance of protein C antigen assays. Thromb Haemostas 1987;57:112-117
40. Mannucci PM, Boyer C, Tripodi A, et al. Multicenter comparison of five functional and two immunological assays for protein C. Thromb Haemostas 1987;57:44-48
41. Franchi F, Tripodi A, Valsecchi C, Mannucci PM. Functional assays of protein C: Comparison of two snake-venom assays with two thrombin assays. Thromb Haemostas 1988;60:145-147
42. Orthner CL, Kolen B, Drohan WN. A sensitive and facile assay for the measurement of activated protein C activity levels in vivo. Thromb Haemostas 1993;69:441-447
43. Pabinger I, Allart CF, Hermans J, Briët E, Bertina RM. Hereditary protein C deficiency: Laboratory values in transmitters and guidelines for the diagnostic procedure. Thromb Haemostas 1992;68:470-474
44. Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briet E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993;341:134-138
45. Francis RB, Seyfert U. Rapid amidolytic assay of protein C in whole plasma using an activator from the venom of Agk-istrodon Contotrix. Am J Clin Pathol 1987;87:619-625
46. Aiach M, Gandrille S. Molecular basis for protein C hereditary deficiency. Haemostasis 1996;26 (Suppl 4):9-19
47. De Stefano V, Finazzi G, Manucci PM. Inherited thrombophilia: Pathogenesis, clinical syndromes and management. Blood 1996;87:3531-3544
48. Zoller B, Garcia de Frutos P, Dahlbäck B. Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood 1995;85:3542-3531
49. Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay. Thromb Haemostas 1993;70:683-690
50. Vigano-D'Angelo S, D'Angelo A, Kaufman MJ, Sholer C, Esmon CT, Comp PC. Protein S deficiency occurs in the nephrotic syndrome. Ann Intern Med 1987;107:42-47
51. D'Angelo A, Vigano-D'Angelo S, Esmon CT, Comp PC. Acquired deficiency of protein S, protein S activity during oral anticoagulation, in liver disease, and in disseminated intravascular coagulation. J Clin Invest 1988;81:1445-1454
52. Comp PC, Thurnau GR, Welsh J, Esmon CT. Functional and immunological protein S levels are decreased during pregnancy. Blood 1986;68:881-885
53. Malm J, Laurell M, Dahlbäck B. Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol 1988;68:437-443
54. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993;82:1989-1993
55. Dahbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor found to be a property of factor V. Proc Natl Acad Sci USA 1994;91:1396-1400
56. 506 of factor V. Lancet 1994;343:1535-1536
57. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994;343:1536-1538
58. Engel H, Zwang L, van Vliet HHDM, Michiels JJ, Stibbe J, Lindemans J. Phenotyping and genotyping of coagulation factor V Leiden. Thromb Haemostas 1996;75:267-269
59. 506 allele as a basis of venous thrombosis. Haemostasis 1996;26:301-314
60. 506 mutation. Evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis. Thromb Haemostas 1997;77:436-439
61. Exner T, Murray B, Chong BH, Chesterman CN. Improved APC-resistance method based on a Russell's Viper Venom clotting test. Thromb Haemostas 1995;73:1119 (Abst)
62. Alhene-Gelas M, Aillaud MF, Bonvarlet MN, Duput G, Juhan-Vague I, Aiach M. Specificity of an assay based on a factor V-depleted plasma in patients carrying the Arg 506 Gln mutation. Thromb Haemostas 1996;75:976-977
63. Aboud MR, Ma DDF. A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation. Br J Haematol 1997;97:798-803
64. Nicolaes GAF, Christella M Thomassan GD, et al. A prothrombinase based assay for the detection of resistance to activated protein C. Thromb Haemostas 1996;76:404-410
65. Van Oerle R, van Pampus L, Tans G, Rosing J, Hamulyák K. The clinical application of a new specific functional assay to detect the factor V Leiden mutation associated with activated protein C resistance. Am J Clin Pathol 1997;107:521-526